Detailed Narrative
FY25: A Year of Transition and Strategic Reset
FY25 was a transitional year for Sastasundar Ventures, marked by resilience and a renewed focus following the settlement of uncertainties related to its partnership with Flipkart Health. The company successfully relaunched its B2C initiatives under the SastaSundar app, now housed in a 100% owned subsidiary. This strategic reset involved exiting the Flipkart-linked Healthbuddy model, which contributed ₹863 crores in FY24, to lay the groundwork for an independent B2C journey.
Mixed Performance Across Business Segments
The SastaSundar B2C business generated ₹144 crores in revenue for FY25, reflecting its nascent stage and an impact from the earlier-than-expected closure of Flipkart Health operations. In contrast, the RetailerShakti B2B business demonstrated strong and consistent growth, nearly doubling its revenue from ₹489 crores in FY24 to approximately ₹941 crores in FY25. The diagnostic vertical contributed approximately ₹3 crores in FY25, positioned as a critical component of the integrated primary healthcare platform.
Profitability Impact and Future Outlook
The strategic reset and the decline in B2C revenue, coupled with a largely unchanged fixed cost base, led to a temporary dip in margins and resulted in negative EBITDA for FY25. However, management expects steady improvement in earnings as the independent B2C platform scales alongside the B2B RetailerShakti platform. The company aims for RetailerShakti to achieve a positive EBITDA margin by the end of the current year (FY26) and targets a 1% overall company EBITDA margin by Q4 FY26, with long-term blended EBITDA margins of 4-5% by FY30.
New Initiatives and Digital Innovation
Sastasundar is focusing on several new initiatives, including the launch of 'JITO' under the SastaSundar brand, which offers quality-identified generic medicines at up to 60% discount. The company has also successfully integrated diagnostic services into its app, gaining good traction. Additionally, SastaSundar podcasts on health and happiness are addressing the lack of reliable health information, aiming to provide honest advice and monetize the platform through advisory services. The 'Quick Health' initiative is also under development, leveraging AI for urgent healthcare needs.
Capital Allocation and Liquidity Management
The company plans to invest approximately ₹150 crores in building its SastaSundar platform and warehouse capabilities, with ₹40 crores invested in FY24 and ₹110 crores planned for FY25 and FY26. Specifically, ₹45-50 crores will be invested in FY26 for technology, including expanding the tech team, software, platforms, and an AI team for counseling. Sastasundar maintains strong liquidity with ₹656 crores in liquid assets as of Q4 FY25, which management believes is sufficient to cover investments and operational needs without raising external capital for the next 2-3 years.
Operational Efficiency and Network Expansion
Sastasundar significantly improved its working capital efficiency, reducing working capital days from 35 in Q4 FY24 to 23 in Q4 FY25, with a long-term target of 15 days by 2030. The company is actively rebuilding its Healthbuddy network post-Flipkart exit, aiming to have around 400 active Healthbuddy partners working closely with the SastaSundar network by the end of the current year. This expansion is crucial for integrating digital innovation with physical reach.